Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma

International Journal of Hematology

Volumn 89, Issue 5, 2009, Pages 636-641

  Murakami, Hirokazu ^a   Shimizu, Kazuyuki ^b   Sawamura, Morio ^c   Suzuki, Kenshi ^d   Sugiura, Isamu ^e   Kosugi, Hiroshi ^f   Shimazaki, Chihiro ^g   Taniwaki, Masafumi ^g   Abe, Masahiro ^h   Takagi, Toshiyuki ⁱ  

^a GUNMA UNIVERSITY   (Japan)

^b Nagoya City Midori General Hospital   (Japan)

^c Shibukawa Medical Center   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^e TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^f OGAKI MUNICIPAL HOSPITAL   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY   (Japan)

^h UNIVERSITY OF TOKUSHIMA   (Japan)

ⁱ Kimitsu Chuou Hospital   (Japan)

Author keywords

Adverse event; Myeloma; Pharmacokinetics; Thalidomide

Indexed keywords

THALIDOMIDE;

ABDOMINAL DISTENSION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXTREMITY NUMBNESS; FATIGUE; FEMALE; GUSTATORY DISTURBANCE; HUMAN; INTESTINE PERFORATION; ISCHEMIC HEART DISEASE; JAPANESE; LEUKOPENIA; LOW DRUG DOSE; LYMPHOPHENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; MUSCLE DISEASE; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMBLING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHARMACOKINETICS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 67749130637     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0314-5     Document Type: Article

References (16)

1. M Attal J-L Harousseau T Facon F Guilhot C Doyen J-G Fuzibet 2003 Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2495 2502
2. SK Kumar SV Rajkumar A Dispenzieri MQ Lacy SR Hayman FK Buadi 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520 10.1182/blood-2007-10-116129
3. W Lenz 1985 Thalidomide embryopathy in Germany, 1959-1961 Prog Clin Biol Res 163C 77 83
4. RJ D'Amato MS Loughnan E Flynn J Folkman 1994 Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 4082 4085
5. A Vacca D Ribatti L Roncali G Ranieri G Serio F Silvestris 1994 Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 503 508 10.1111/j.1365-2141.1994.tb08304.x
6. S Singha J Mehta R Desikan D Ayers P Roberson P Eddlemon 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl H Med 341 1565 1571
7. WD Figg S Raje KS Bauer A Tompkins D Venzon R Bergan 1999 Pharmacokinetics of thalidomide in an elderly prostate cancer population J Pharm Sci 88 121 125
8. BR Simmons RM Lush WD Figg 1997 A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum Anal Chim Acta 339 91 97 10.1016/S0003-2670(96)00494-1 (Pubitemid 27096505)
9. B Barlogie M Zangari T Spencer A Fassas E Anaissie A Badros 2001 Thalidomide in the management of multiple myeloma Semin Haematol 38 250 259 (Pubitemid 32717662)
10. BGM Durie 2002 Low-dose thalidomide in myeloma: efficacy and biologic significance Semin Oncol 29 Suppl 17 34 38
11. RE Johnston SH Abdalla 2002 Thalidomide in low doses in effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia Leukemia Lymphoma 43 351 354
12. H Murakami H Handa M Abe S Iida A Ishii T Ishikawa 2007 Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma Eur J Haematol 79 234 239 (Pubitemid 47231170)
13. Y Hattori S Okamoto N Shimada T Kakimoto K Morita Y Tanigawara 2008 Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile Cancer Sci 99 1243 1250
14. SJ Matthews C McCoy 2003 Thalidomide: a review of approved and investigational uses Clin Therap 25 356 361
15. SV Rajkumar L Rosiñol M Hussein J Catalano W Jedrzejczak L Lucy 2008 Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma J Clin Oncol 26 2171 2177
16. FH Noormohamed MS Youle CJ Higgs KA Kook DA Hawkins AF Lant 1999 Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects AIDS Res Human Retroviruses 15 1047 1052